Vertex has continued to deliver breakthrough drugs for cystic fibrosis while exploring treatments for other illnesses ...

Amgen (AMGN) has drawn fresh attention after recent trading left the shares at $379.42, capping a period in which returns ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

When measured against the market's most prolific capital-return leaders, Amgen’s ability to maintain this level of ...

Amgen (NASDAQ:AMGN) executives outlined the company’s oncology research and development priorities and provided updates on ...

Amgen Inc. (NASDAQ:AMGN) is one of the best immunotherapy stocks to buy according to hedge funds. On February 12, Amgen Inc. ...

Amgen’s Lumakras receives US FDA approval for patients with KRAS G12C-mutated locally advanced or metastatic NSCLC: Thousand Oaks, California Monday, May 31, 2021, 11:00 Hrs [IS ...

Piper Sandler Virtual Novel Targets in Immunology Symposium February 12, 2026 5:00 PM ESTCompany ParticipantsPaul Burton - Senior VP ...

The drug, MariTide, also helped patients with obesity and Type 2 diabetes lose up to 17% of their weight after a year. The company said it did not observe a plateau in either group of patients, which ...

If you have $10,000 that you won’t need to spend anytime soon, there are ways to derive passive income from that money. Among the easiest strategies is to buy and hold a handful of dividend-paying ...

Roughly a year and a half after the introduction of a shareholder lawsuit, Amgen has lost its bid to toss the case accusing the California biotech giant of concealing a massive tax bill with the IRS.

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. New data from a mid-stage study of an Amgen obesity drug showed that it ...